BTIG Research Raises LifeMD (NASDAQ:LFMD) Price Target to $14.00

LifeMD (NASDAQ:LFMD) had its price objective lifted by equities researchers at BTIG Research from $13.00 to $14.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 40.00% from the stock’s current price.

Separately, HC Wainwright boosted their price objective on shares of LifeMD from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.40.

LifeMD Price Performance

NASDAQ LFMD opened at $10.00 on Tuesday. LifeMD has a 12-month low of $1.40 and a 12-month high of $12.01. The firm’s fifty day simple moving average is $9.06 and its two-hundred day simple moving average is $7.64. The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $403.70 million, a P/E ratio of -14.29 and a beta of 1.43.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $44.86 million for the quarter, compared to analysts’ expectations of $40.65 million. Analysts forecast that LifeMD will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeMD

Several hedge funds have recently added to or reduced their stakes in LFMD. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 266.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $38,000 after buying an additional 3,348 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in LifeMD by 24.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 25,200 shares of the company’s stock valued at $158,000 after acquiring an additional 5,000 shares during the period. Dorsey Wright & Associates purchased a new stake in LifeMD in the 3rd quarter worth approximately $37,000. HighMark Wealth Management LLC purchased a new stake in LifeMD in the 3rd quarter worth approximately $38,000. Finally, Worth Venture Partners LLC acquired a new stake in shares of LifeMD during the 3rd quarter worth approximately $64,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.